Retatrutide’s mechanism is what sets it apart. Rather than acting on one receptor, it is engineered to bind three — and the interplay between them is the subject of active research.
GLP-1: appetite and glucose response
The GLP-1 pathway is the best understood. In research it is associated with slowed gastric emptying, reduced appetite signaling, and glucose-dependent insulin secretion.
GIP: the amplifier
GIP is a second incretin hormone. Studied alongside GLP-1 (as in tirzepatide), it appears to enhance the metabolic response and may moderate some tolerability signals.
Glucagon: the energy-side pathway
Glucagon is often thought of only for raising blood sugar, but the receptor is also linked in research to energy expenditure and hepatic lipid metabolism. Retatrutide’s addition of glucagon activity is the mechanistic reason researchers hypothesize its larger observed effects.
Take our 60-second quiz for a personalized recommendation and unlock 35% off your first order of USA-made, COA-verified GLP.
For the trial data behind these mechanisms, read what the retatrutide clinical research has shown, and see the side-by-side comparison of all three peptides.
For research and educational use only. The information here is not medical advice and RDAmd products are not intended to diagnose, treat, cure, or prevent any disease or for human consumption. Retatrutide is an investigational compound and is not approved by the FDA. Always consult a qualified professional.
